Estimated market cap $155.61MShares outstanding from the company’s latest SEC filing (all share classes, each priced at its own close; ADRs converted to ADS) × last close from Tiingo. Updated daily. This figure: shares as of Oct 30, 2026, last close Nov 13, 2026.121.57M shares, shares as of Oct 30, 2026CIK 1434316The SEC’s Central Index Key, the number it uses to identify every company and person that files.
Insider trades, 12 mo
0 buys · 7 sells
$336.4K sold, open market
Congress trades, 24 mo
—
No disclosed trades
13F holders
…
Lobbying, 12 mo
—
No lobbying filings
Federal contracts, 12 mo
—
None matched
Ask your AI:
Latest 10-Q
What changed in Fate Therapeutics, Inc.'s latest quarterly report, compared with the one before.
Loading…
Insider trades
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
Loading…
13F holders
Funds that report this stock, checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Loading…
Top 10 holders.Premium lists every holder, with CSV downloads.
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
Loading…
Lobbying
What Fate Therapeutics, Inc. and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
Loading…
H-1B labor applications at Fate Therapeutics, Inc.
3 certified in 12 mo
Labor condition applications decided by the Department of Labor, matched to Fate Therapeutics, Inc. by employer name. An application is not a hire.
Median yearly wage offered, full-time certified applications, Jul 2025 to Jun 2026: —The wage the employer offered, as filed, with its unit. The yearly figure restates it per year (hourly x 2,080, weekly x 52, every two weeks x 26, monthly x 12) from the low end of the offered range. It is not what the worker was paid.
H-1B labor applications decided at Fate Therapeutics, Inc. by quarter
We match the employer's name to a public company automatically, including a reviewed list of subsidiaries. A subsidiary can be missed and a similar name can be matched wrongly. The files carry no worker names.
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
13F holders, Q3 2026Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
92
33.0% of shares · 17 added
Latest 10-Q
Q3 2026
What changed in Fate Therapeutics, Inc.'s latest quarterly report, compared with the one before.
Filed Nov 5, 2026 · Quarter ended Sep 30, 2026
Summary text goes here once it has loaded. Summary text goes here once it has loaded.
Summary text goes here once it has loaded.
Summary text goes here once it has loaded.
AI summary of changes vs the prior report. Written by AI from the paragraphs that changed, and checked against them. This is information, not investment advice.
Compared with the 10-Q for the quarter ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.
Open-market trades from Form 4. 10b5-1 marks a plan set in advance.Open-market buys and sales by officers, directors and 10% owners, from SEC Form 4. A plan set in advance is marked 10b5-1.
Recent insider trades
How the stock has done since the trade date, measured against the S&P 500 over the same days. It describes the stock, not the trader's actual gain or loss.
92 funds report FATE. Values checked against market prices.Fund managers with over $100 million in US-listed stocks file a 13F each quarter, up to 45 days after quarter end. Long positions only.
Funds own 60% of shares (Q2 2026)Fund managers with more than $100 million in US-listed stocks file a 13F each quarter. It lists their long stock positions only (shorts, options and bonds are left out) and can arrive up to 45 days after the quarter ends, so this is a snapshot of the quarter end. We add up the shares every fund reports in this class and divide by the shares outstanding. The total can pass 100%: the same shares are often reported by more than one manager (an adviser and the fund it runs), lent shares can be reported twice, and the share count can be out of date after buybacks. We divided 71.73M reported shares by 119.82M shares, from the company’s SEC filing as of Aug 6, 2026.
155 funds hold the stock.
Q3 2026: 33% · 5,560 of ~8,900 funds reported so farFunds have 45 days after a quarter ends to file. This quarter’s reports are still arriving, so the figure only counts the funds that have filed so far and will usually rise.
Q2 202569%
Q3 202570%
Q4 202563%
Q1 202664%
Q2 202660%
Q3 2026 (so far)33%
Q3 2026. 11 new, 17 added to, 32 trimmed, 74 exited since Q2 2026.
One of these funds reports its values in thousands of dollars; its figures are shown in dollars.
Download CSVEvery fund that holds FATE, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Trades by members of Congress
Disclosed in dollar ranges, up to 45 days after the trade.Members of Congress, their spouses and dependent children report trades in dollar ranges, up to 45 days after the trade.
Recent congressional trades
Member
Transaction
Amount
Traded → disclosed
Since tradeHow the stock has done since the trade date, measured against the S&P 500 over the same days. It describes the stock, not the trader's actual gain or loss.
What Fate Therapeutics, Inc. and its lobbying firms report each quarter.A company that lobbies with its own staff reports its expenses; a lobbying firm it hires reports the income it received. We count both.
No recent lobbying filings for this company.
Institutional ownership over time
How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.
Funds holding the stock
Shares they report
Funds holding the stock by quarter
Q4 2013
16
—
3.93M
$24.7M
Q1 2014
21
+5
9.56M
$92.8M
Q2 2014
22
+1
9.89M
$62.7M
Q3 2014
22
0
10.27M
$52.6M
Q4 2014
23
+1
10.31M
$51.8M
Q1 2015
25
+2
10.61M
$51.9M
Q2 2015
39
+14
18.02M
$116.6M
Q3 2015
44
+5
18.35M
$97.8M
Q4 2015
54
+10
18.61M
$62.7M
Q1 2016
45
-9
15.77M
$28.4M
Q2 2016
39
-6
14.09M
$24.0M
Q3 2016
40
+1
19.48M
$60.8M
Q4 2016
37
-3
23.69M
$59.3M
Q1 2017
53
+16
25.64M
$116.7M
Q2 2017
60
+7
26.61M
$86.2M
Q3 2017
74
+14
25.41M
$100.6M
Q4 2017
78
+4
35.05M
$214.1M
Q1 2018
90
+12
39.41M
$384.7M
Q2 2018
103
+13
43.12M
$489.0M
Q3 2018
116
+13
54.99M
$895.8M
Q4 2018
121
+5
60.08M
$770.8M
Q1 2019
123
+2
60.80M
$1.1B
Q2 2019
136
+13
63.21M
$1.3B
Q3 2019
149
+13
74.96M
$1.2B
Q4 2019
147
-2
73.08M
$1.4B
Q1 2020
156
+9
80.07M
$1.8B
Q2 2020
202
+46
85.97M
$2.9B
Q3 2020
211
+9
87.81M
$3.5B
Q4 2020
248
+37
87.11M
$7.9B
Q1 2021
260
+12
93.96M
$7.7B
Q2 2021
272
+12
94.55M
$8.2B
Q3 2021
266
-6
95.91M
$5.7B
Q4 2021
250
-16
97.20M
$5.7B
Q1 2022
248
-2
101.27M
$3.9B
Q2 2022
233
-15
109.58M
$2.9B
Q3 2022
239
+6
109.25M
$2.4B
Q4 2022
228
-11
105.67M
$1.1B
Q1 2023
181
-47
113.12M
$644.8M
Q2 2023
188
+7
109.15M
$519.6M
Q3 2023
170
-18
95.49M
$202.5M
Q4 2023
159
-11
98.89M
$369.8M
Q1 2024
167
+8
131.06M
$961.9M
Q2 2024
182
+15
123.84M
$406.2M
Q3 2024
164
-18
116.59M
$408.0M
Q4 2024
159
-5
101.72M
$166.5M
Q1 2025
132
-27
96.61M
$76.3M
Q2 2025
139
+7
79.81M
$89.1M
Q3 2025
143
+4
80.64M
$101.6M
Q4 2025
147
+4
72.27M
$71.1M
Q1 2026
159
+12
74.12M
$88.9M
Q2 2026
156
-3
71.73M
$193.6M
Q3 2026
92
-64
40.08M
$95.0M
Each point is a quarter-end, from Q4 2013 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.
Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.
The history follows the company's current CUSIP number (31189P102). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q4 2013) can be later than the stock's first appearance in 13F reports.
Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.
A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.